Current view on the safety of PEGylated biologics in hemophilia treatment
Andreas BaumannBayer AG13342 Berlin, Germany+49 30 468-17450andreas.baumann@bayer.com Disclosure...
Read More
Category: THE ROYAL PALACE 7sept
Type 1 VWD caused by a novel dominant p.Thr274Pro mutation localized in VWF propeptide
M.T. Pagliari1, L. Baronciani2, G. Cozzi2, P. Colpani2, F. Peyvandi2,31Fondazione IRCCS Ca’ Granda...
Read More
Evaluation of the von Willebrand factor (VWF) inhibitor in a large cohort of European and Iranian patients previously diagnosed with type 3 von Willebrand disease (VWD) enrolled into the 3WINTER-IPS Project
Luciano Baronciani1, Ulrich Budde2, Francesca Stufano1, Flora Peyvandi1,3, Anne Goodeve4, Reinhard...
Read More
Evaluation of platelet-dependent VWF activity on a heterogeneous group of von Willebrand disease patients using four different methods: two VWF:GPIbM and two VWF:RCo assays
Colpani Paola1, Baronciani Luciano1, Stufano Francesca1, Boscarino Marco1, Bucciarelli Paolo1,...
Read More
The presence of inhibitors against von Willebrand factor and factor VIII in the same patient: a case report
Désirée Coen Herak1, Marija Milos1, Silva Zupancic-Salek2, Renata Zadro1,31Department of...
Read More